NIH Study for COVID-19
COVID-19 Study for Michigan Residents
The study team hopes to find out if giving anti-SARS-CoV-2 hyperimmunoglobulin (hIVIG) to people early in their infection with COVID-19, before the body has had a chance to make its own antibodies, can help prevent bad effects from COVID-19 and enable them to stay out of the hospital.
If you join this study, you will be compensated for your time and travel, and receive either study drug (hIVIG) or placebo given through a vein in the arm as a single dose. You will also get the usual treatment and care for COVID-19 according to local guidelines which could include monoclonal antibody therapy. The study lasts 28 days with some of the scheduled study visits taking place over the phone.
For more information about this study, download the Trial Summary.
What is the type of clinical trial being conducted?
This study is a randomized, double-blind, placebo-controlled trial. Participants will have a 50-50 chance (like tossing a coin) of being assigned to the “active” study drug (hIVIG) or placebo (salt water with no study drug).
Who can take part in the study?
You may be able to join the study if you:
- Are 55 or older, OR are 18 or older with a weakened immune system
- Have tested positive for COVID-19 within the past 5 days
- Are not having symptoms, OR have had symptoms for 5 days or less
- Are not currently hospitalized
Interested in taking part in a clinical trial?
If you are interested in taking part in one of our active clinical trials, fill out the form below and one of our team members will reach out to you with more information.
Interested in Other Enrolling Clinical Trials?
All of our studies are regulated by the Food and Drug Administration (FDA). To find out more, click on the links below.